Abbott, a leader in diabetes tech with one of the biggest lines of continuous glucose monitors, announced this week that it's ...

WASHINGTON, D.C. — The Food and Drug Administration (FDA) announced that Abbott has initiated a voluntary recall for a ...

We are thrilled to announce our collaboration with Abbott, integrating its world-leading FreeStyle Libre technology 2 as our first CGM partner, marking a significant milestone as we bring our ...

MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced that Abbott’s FreeStyle Libre 3 ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

twiist™ AID system powered by Tidepool expected to launch Q2 2025 in the U.S. with Abbott's FreeStyle Libre® 3 Plus sensor MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a ...

Sequel Med Tech announced today that it integrated its twiist automated insulin delivery (AID) with the Abbott FreeStyle Libre 3 Plus sensor.

A year to the day after declaring the FDA’s clearance of its automated insulin pump, Sequel Med Tech announced that its first connected continuous glucose monitor will be Abbott’s FreeSty | Greenlit ...

Sequel Med Tech has announced that Abbott’s FreeStyle Libre 3 Plus sensor will be the first continuous glucose monitoring device to work with its twiist Automated Insulin Delivery (AID) System powered ...

(Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast.

Sequel Med Tech has announced that Abbott’s FreeStyle Libre 3 Plus sensor will be the first continuous glucose monitoring device to work with its twiist Automated Insulin Delivery (AID) System powered ...